Gilead Sciences Inc. ($GILD) Stock Forecast: Down 1.9% Today

What is Gilead Sciences Inc.?

GILD (Gilead Sciences Inc.) is a renowned biopharmaceutical company known for its focus on antiviral drugs, HIV treatments, and ventures into oncology. The stock experienced a strong bearish movement today in the market.

Why is Gilead Sciences Inc. going down?

GILD stock is down 1.9% on Jan 5, 2026 15:46

• Gilead Sciences Inc. (GILD) faced a bearish market movement possibly due to the news of Repare Therapeutics announcing Gilead's acquisition of RP-3467 for up to $30 million. This acquisition might have raised concerns among investors about the potential impact on Gilead's financials or strategic direction.
• The appointment of Sung Lee, a finance leader with experience in biopharmaceutical companies including Gilead Sciences, to Tango Therapeutics' Board of Directors might have diverted some attention and resources away from Gilead, leading to a negative sentiment in the market.
• The strategic shift towards oncology and diversified product offerings by another company could have also influenced investors to reevaluate Gilead's position in the competitive landscape, contributing to the bearish movement.
• The evaluation of Gilead Sciences Inc. as a potential investment, contrasting its stability with operational risks like patent cliffs and trial failures, might have prompted some investors to reposition their portfolios, impacting GILD's stock performance negatively.

GILD Price Chart

GILD Technical Analysis

GILD News

Tango Therapeutics Appoints Sung Lee to Board of Directors

Tango Therapeutics has appointed Sung Lee to its Board of Directors. Mr. Lee brings over 20 years of finance leadership experience from biopharmaceutical and technology industries, including prior roles at Cytokinetics, Vir Biotechnology, and Gilead Sciences. His expertise is expected to be crucial as Tango Therapeutics advances its lead program, vopimetostat, into registrational studies.

https://finance.yahoo.com/news/tango-therapeutics-appoints-sung-lee-120000584.html

Gene Therapy Market Is Going to Boom Worldwide | GlaxoSmithKline

Coherent Market Insights predicts substantial growth for the Gene Therapy Market from 2025 to 2032 due to increased demand, expanding applications, and technological advancements. The report offers a comprehensive analysis of market size, revenue trends, key growth drivers, challenges, and opportunities, including a detailed regional assessment and competitive landscape analysis. Top companies covered include GlaxoSmithKline plc, Bluebird Bio Inc., and Adaptimmune Therapeutics plc, with segmentation by therapy type, vector type, and disease indication.

https://www.openpr.com/news/4335362/gene-therapy-market-is-going-to-boom-worldwide-glaxosmithkline

The Truth About Gilead Sciences Inc (GILD): Hidden Giant or Boomer Stock Trap?

This article evaluates Gilead Sciences Inc (GILD) as a potential investment, contrasting its perception as a "boomer stock" with its strong fundamentals in drug pipeline, cash flow, and dividend. It highlights Gilead's established revenue from HIV and antiviral drugs, its ventures into oncology, and its appeal for income-seeking investors, while also addressing operational risks like patent cliffs and trial failures. The analysis concludes that GILD offers stability and biotech upside for long-term investors, distinguishing it from popular meme stocks.

https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-gilead-sciences-inc-gild-hidden-giant-or-boomer-stock/68459974

Merck & Co. Inc.: How a 130-Year Pharma Giant Is Rebuilding Its Flagship Around Oncology and Beyond

Merck & Co. Inc. is transitioning from a reliance on its blockbuster drug Keytruda to a diversified, oncology-centric product platform. This strategy involves expanding its portfolio beyond Keytruda to include a broad range of cancer immunotherapies, vaccines, animal health solutions, and data-driven R&D capabilities. The company aims to build a resilient, multi-pillar product ecosystem before patent cliffs impact Keytruda, focusing on oncology, vaccines, and advanced R&D to drive future growth and maintain a competitive edge against rivals like Pfizer and Bristol Myers Squibb.

https://www.ad-hoc-news.de/boerse/news/ueberblick/merck-and-co-inc-how-a-130-year-pharma-giant-is-rebuilding-its/68459302

Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million

Repare Therapeutics has announced that Gilead Sciences will acquire its polymerase theta (Polθ) ATPase inhibitor, RP-3467, for up to $30 million. This transaction will provide Repare with a $25 million upfront payment and a potential additional $5 million, which has increased the estimated cash payment for Repare shareholders to approximately US$2.20 per common share as part of a larger acquisition by XenoTherapeutics. RP-3467 is a clinical-stage precision oncology therapeutic being evaluated in a Phase 1 trial for various advanced cancers.

https://www.citybiz.co/article/788439/repare-therapeutics-announces-gilead-acquisition-of-rp-3467-for-up-to-30-million/

Trending Today

Astera Labs Inc ($ALAB) Stock Forecast: Up 6.9% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 5.1% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Down 5.0% Today

First Solar Inc. ($FSLR) Stock Forecast: Down 11.0% Today

Sysco Corporation ($SYY) Stock Forecast: Down 1.2% Today

FuelCell Energy ($FCEL) Stock Forecast: Down 7.6% Today

Circle Internet Group ($CRCL) Stock Forecast: Down 5.4% Today

Western Digital Corporation ($WDC) Stock Forecast: Down 8.6% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Up 5.3% Today

DaVita Inc. ($DVA) Stock Forecast: Down 3.8% Today

Gilead Sciences Inc. Price History

09.03.2025 - GILD Stock was down 5.1%

• Gilead Sciences (GILD) exhibited bearish movement, closing at $112.39 with a +0.45% change from the previous close.
• The positive momentum surrounding Gilead Sciences amid market decline could be linked to internal developments within the company.
• Various factors such as tariff tensions, geopolitical events, and uncertainties related to the Fed may have influenced the overall market sentiment, potentially overshadowing Gilead's performance.
• Attention from investors may have shifted towards other companies like Amazon and Alphabet, affecting Gilead Sciences' performance and contributing to its bearish movement.

05.00.2026 - GILD Stock was down 1.9%

• Gilead Sciences Inc. (GILD) faced a bearish market movement possibly due to the news of Repare Therapeutics announcing Gilead's acquisition of RP-3467 for up to $30 million. This acquisition might have raised concerns among investors about the potential impact on Gilead's financials or strategic direction.
• The appointment of Sung Lee, a finance leader with experience in biopharmaceutical companies including Gilead Sciences, to Tango Therapeutics' Board of Directors might have diverted some attention and resources away from Gilead, leading to a negative sentiment in the market.
• The strategic shift towards oncology and diversified product offerings by another company could have also influenced investors to reevaluate Gilead's position in the competitive landscape, contributing to the bearish movement.
• The evaluation of Gilead Sciences Inc. as a potential investment, contrasting its stability with operational risks like patent cliffs and trial failures, might have prompted some investors to reposition their portfolios, impacting GILD's stock performance negatively.

07.10.2024 - GILD Stock was up 6.5%

• Gilead Sciences has consistently outperformed the market over the past 20 years, showcasing strong growth and investor confidence.
• The upcoming Q3 earnings report has likely sparked investor optimism, especially regarding the performance of GILD's HIV franchise and oncology sales.
• Despite a slight market dip, Gilead Sciences managed to gain, indicating resilience and potential positive news or market sentiment surrounding the company.

17.09.2025 - GILD Stock was up 5.3%

• A Buy rating and raised price target for Gilead Sciences by Citigroup analyst boosted investor confidence in the stock.
• Positive sentiment from CNBC's "Final Trades" segment likely attracted more attention from traders, contributing to the bullish movement.
• Endorsement from industry experts and media coverage could have sparked increased buying interest, leading to the strong bullish movement in GILD stock today.

06.04.2025 - GILD Stock was down 5.1%

• GILD saw a downward trend today after disappointing first-quarter results, particularly in the oncology sector.
• Advice for investors to adopt a cautious approach indicates uncertainty about the stock in the near future.
• The market's response to the earnings shortfall underscores the significance of consistent performance in crucial business divisions, like oncology, to uphold investor trust in pharmaceutical firms like GILD.

08.07.2025 - GILD Stock was up 9.8%

• GILD stock had a strong uptrend today.
• Strategies to generate monthly dividend income from owning GILD shares before Q2 earnings are highlighted.
• The surge in the stock price may be linked to positive investor outlook on GILD's upcoming earnings and dividend potential.
• Favorable market sentiment towards income-generating stocks like GILD might have contributed to the stock's uptick.

08.07.2025 - GILD Stock was up 8.9%

• In the second quarter, Gilead Sciences posted strong financial results, exceeding expectations with an adjusted EPS of $2.01 and revenue of $7.08 billion. This robust performance likely drove the positive movement in the stock price.
• Sales of key products such as Biktarvy and Descovy showed notable increases of 9% and 35% respectively, demonstrating the company's ability to meet market demand effectively and boost revenue.
• Investors showed optimism before Gilead Sciences' Q2 earnings release, fueling the surge in the stock price as they looked to benefit from potential dividend income and the company's growth prospects.

10.03.2025 - GILD Stock was down 5.6%

• GILD had a strong bearish movement despite a slight increase in its stock price in the previous trading day.
• The conflicting reports of GILD ascending while the market falls may have caused confusion among investors, leading to profit-taking and a bearish trend.
• Investors might be concerned about Gilead Sciences falling behind the market, possibly due to competition in the biopharmaceutical sector or delays in drug development.
• The overall market sentiment and the specific news about GILD's performance could have contributed to the bearish movement of the stock today.

12.01.2025 - GILD Stock was up 7.5%

• Gilead Sciences experienced a notable increase in its stock price due to the announcement of better-than-expected fourth-quarter financial results and optimistic FY25 adjusted EPS guidance.
• The market responded positively to Gilead's strategic collaborations, including the recent partnership with LEO Pharma involving significant upfront payments and potential milestones.
• Despite prevailing market pessimism and concerns from institutional investors about Gilead Sciences options trading, the company's robust performance and promising future outlook appear to have driven the stock upwards.

12.01.2025 - GILD Stock was up 8.0%

• Gilead Sciences reported Q4 earnings, with analysts expecting $1.70 EPS and $7.14B in revenue, potentially exceeding forecasts and boosting investor confidence.
• The company's deal with LEO Pharma, including significant upfront payments and future milestones, may have positively influenced market sentiment towards Gilead.
• Despite some bearish options trading activity, the overall positive outlook on GILD's earnings and performance in key therapeutic areas like HIV and oncology likely contributed to the bullish movement.
• Investors are closely watching Gilead's HIV franchise performance and oncology sales, indicating a strong interest in the company's core revenue-generating segments.

12.01.2025 - GILD Stock was up 7.1%

• Gilead Sciences experienced a strong bullish movement today following the release of its Q4 financial results and optimistic outlook for 2025.
• The company reported a 6% increase in Q4 revenue, surpassing analyst expectations, and raised its dividend, signaling financial strength and confidence in future performance.
• The market reacted positively to Gilead's announcement of launching Lenacapavir for HIV prevention, indicating potential growth opportunities in its product pipeline.
• Overall, Gilead's solid financial performance and strategic developments have instilled investor confidence, driving the stock price higher in today's trading session.

31.09.2025 - GILD Stock was down 0.4%

• The bearish movement in GILD stock today could be attributed to investors' uncertainty ahead of the Q3 earnings report, despite the company's strong performance in the HIV sector.
• The long-term outperformance of Gilead Sciences in the market over the past 20 years might not be enough to offset current concerns about challenges in its Cell Therapy business, leading to a sell-off.
• Investors may be cautious due to the potential impact of the FDA approvals and how they might translate into revenue, causing some to take profits or reevaluate their positions in GILD stock.